Methods and compositions for manufacturing extracellular matrix
Embodiments herein include methods, kits, and compositions for manufacturing extracellular matrix (ECM). In some embodiments, the methods comprise differentiating fibroblasts into induced pluripotent stem cells, expanding the induced pluripotent stem cells, and differentiating the induced pluripotent stem cells into fibroblasts. The fibroblasts can produced mature ECM, which can be isolated and used for medical and/or cosmetic products and procedures.
1. A method of manufacturing extracellular matrix (ECM), the method comprising:
(a) culturing first fibroblasts with one or more de-differentiation factors, thereby de-differentiating the first fibroblasts into induced Pluripotent Stem Cells (iPSCs);
(b) culturing the iPSCs with one or more fibroblast differentiation factors, thereby differentiating the iPSCs into second fibroblasts;
(c) culturing the second fibroblasts in a solution comprising serum at an initial concentration of 0.1% to 20% (v/v), until the second fibroblasts produce mature collagens;
(d) gradually reducing the concentration of serum in the fibroblast culture of step (c) by performing multiple rounds of replacing a portion of the serum-containing solution of step (c) with a serum-free solution over a period of at least 5 days such that there is an at least 95% reduction in the concentration of serum (v/v),
wherein gradually reducing the concentration of serum results in the second fibroblasts producing soluble mature ECM without substantially degrading the ECM; and
(e) isolating the soluble mature ECM from the second fibroblasts, wherein isolating the soluble mature ECM comprises contacting the second fibroblasts with dextranase,
thereby manufacturing the ECM.
2. The method of claim 1 , further comprising expanding the iPSCs prior to (b).
3. The method of claim 1 , wherein the culturing of the second fibroblasts is in normoxia.
4. The method of claim 1 , wherein culturing the second fibroblasts does not comprise culturing mesenchymal stem cells (MSCs).
5. The method of claim 1 , wherein the method does not comprise differentiating any of: an embryonic stem (ES) cell, a bone marrow multipotent stem cell, an ES-derived MSC, or a non-multipotent neonatal foreskin fibroblast cell line.
6. The method of claim 1 , wherein the ECM comprises a triple-helical or non-reducible gamma-form fibrillary collagen, or both.
7. The method of claim 1 , wherein the first fibroblasts comprise adult dermal fibroblasts.
8. The method of claim 1 , wherein isolating the ECM comprises purifying the ECM, thereby manufacturing a composition that is at least about 80% w/w ECM.
9. The method of claim 8 , wherein purifying the ECM comprises contacting the ECM with an acidic buffer.
10. The method of claim 1 , wherein the production of ECM by the production fibroblasts comprises production of nanostructures comprising soluble ECM, the nanostructures having a greatest diameter of at least 200 nm.
11. The method of claim 1 , further comprising manufacturing a cosmetic product comprising the ECM.
12. The method of claim 7 , wherein the first fibroblasts comprise an adult dermal biopsy fibroblast.
13. The method of claim 1 , wherein the second fibroblasts are cultured in the second solution for at least two weeks prior to gradually reducing the concentration of serum.
14. A method of manufacturing extracellular matrix (ECM), the method comprising:
(a) providing fibroblasts in a medium comprising serum at a concentration of 0.1% to 20% (v/v);
(b) gradually reducing the concentration of serum in the medium comprising fibroblasts by performing multiple rounds of replacing a portion of the serum-containing medium of step (a) with a serum-free medium until the medium contains no more than 5% of the concentration of serum in step (a), wherein the gradual reducing of the concentration of serum is performed over a period of at least 5 days,
wherein gradually reducing the concentration of serum results in the fibroblasts producing soluble mature ECM without substantially degrading the ECM;
(c) following (b), culturing the fibroblasts for at least about 2 weeks, whereby the fibroblasts produce soluble mature ECM comprising triple-helical or non-reducible gamma-form fibrillary collagen, or both, thereby producing a solution comprising the fibroblasts and the soluble mature ECM; and
(d) isolating the soluble mature ECM comprising triple-helical or non-reducible gamma-form fibrillary collagen from the fibroblasts, wherein isolating the soluble mature ECM comprises contacting the soluble mature ECM and fibroblasts with dextranase,
thereby manufacturing the ECM.
15. The method of claim 14 , wherein
i) a quantity of fibroblasts in the medium at the start of (b) is at least 0.7× of
ii) a quantity of fibroblasts in the medium when the medium contains no more than 5% of the concentration in the serum.
16. The method of claim 14 , wherein gradually reducing the amount of serum is done without cell expansion or cell subculture.
17. The method of claim 14 , wherein at least about 90% of the fibroblasts in the solution are in a G 0 cell cycle phase.
18. The method of claim 14 , wherein fewer than 1% of the fibroblasts in the solution are undergoing apoptosis.
19. The method of claim 14 , wherein the solution comprises nanostructures comprising the soluble ECM, said nanostructures having a greatest diameter of 200 nm to 10,000 nm.
20. The method of claim 14 , further comprising manufacturing a cosmetic product compromising the ECM.
21. The method of claim 14 , wherein the solution comprising the fibroblasts and the ECM comprises nanostructures comprising the ECM, the nanostructures having a greatest diameter of at least 200 nm.
22. The method of claim 14 , wherein the fibroblasts are cultured in the medium comprising serum at a concentration of 0.1% to 20% (v/v) for at least two weeks prior to gradually reducing the concentration of serum.
23. A method of manufacturing extracellular matrix, the method comprising:
(a) culturing a first fibroblast with one or more de-differentiation factors, thereby de-differentiating the first fibroblast into an induced Pluripotent Stem Cell (iPSC);
(b) expanding the iPSC into iPSCs;
(c) culturing the expanded iPSCs with one or more fibroblast differentiation factors, thereby differentiating the expanded iPSCs into second fibroblasts;
(d) culturing the second fibroblasts in a solution comprising serum at an initial concentration of 0.1% to 20% (v/v), until the second fibroblasts produce mature collagens;
(e) gradually reducing the concentration of serum in the fibroblast culture of step (d) by performing multiple rounds of replacing a portion of the serum-containing solution of step (d) with a serum-free solution over a period of at least five days such that there is at least a 95% reduction in the concentration of serum,
wherein gradually reducing the concentration of serum results in the second fibroblasts producing soluble mature ECM without substantially degrading the ECM,
whereby the second fibroblasts produce soluble mature extracellular matrix (ECM) comprising a triple-helical or non-reducible gamma-form fibrillar collagen, or both; and
(f) isolating the soluble mature ECM from the second fibroblasts, thereby manufacturing the ECM.
24. The method of claim 23 , wherein the production of ECM by the second fibroblasts comprises production of nanostructures comprising the soluble ECM, the nanostructures having a greatest diameter of at least 200 nm.
25. The method of claim 23 , further comprising manufacturing a cosmetic product comprising the ECM.
26. The method of claim 23 , wherein the second fibroblasts are cultured in the second solution for at least two weeks prior to gradually reducing the concentration of serum.